Search Tag: baricitinib

ICU Management

2021 03 Sep

A study was conducted to evaluate the efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor, in combination with standard of care for the treatment of hospitalised patients with COVID-19. A total of 1525 participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America and South America. COVID-19...Read more